Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the Data and Safety Monitoring Board (DSMB) has cleared the continuation of its Phase 1/2 OCU410 ArMaDa clinical trial. This trial is …
Ocugen’s Gene Therapy Trial for Dry AMD Advances Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will present at the Oppenheimer Movers in Rare Disease Summit in New York City …
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that Dr. Shankar Musunuri, the company’s Chairman, CEO, and Co-Founder, will present at NobleCon20, Noble Capital Markets’ 20th Annual Emerging Growth …
Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received orphan medicinal product designation from the European Medicines Agency (EMA) for OCU410ST, a promising treatment for ABCA4-associated retinopathies including Stargardt disease, …
Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has unveiled encouraging preliminary data from the Phase 1 portion of its OCU410 ArMaDa clinical trial, aimed at treating geographic atrophy (GA) secondary …
Ocugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic Atrophy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reported its financial results for the third quarter of 2024, highlighting significant advancements in its gene therapy programs and financial strategies. The …
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to host an in-person Clinical Showcase on Tuesday, November 12, 2024, at the Nasdaq MarketSite in Times Square, New York City, …
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the …
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to host a conference call and live webcast to discuss its financial results for the third quarter of 2024. The event is …
Ocugen Announces Third Quarter Financial Results Conference Call Read More MALVERN, PA — Dr. Shankar Musunuri, Chairman and CEO of Ocugen, Inc. (NASDAQ: OCGN), is set to join a panel discussion at the upcoming 2024 Maxim Healthcare Virtual Summit. Scheduled from …
Ocugen’s CEO to Present at 2024 Maxim Healthcare Virtual Summit Read More